"Darbepoetin alfa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant protein which stimulates ERYTHROPOIESIS used to treat ANEMIA.
| Descriptor ID |
D000068256
|
| MeSH Number(s) |
D12.776.395.240.150.500
|
| Concept/Terms |
Darbepoetin alfa- Darbepoetin alfa
- Novel Erythropoiesis Stimulating Protein
- NESP
- Darbepoietin alfa
|
Below are MeSH descriptors whose meaning is more general than "Darbepoetin alfa".
Below are MeSH descriptors whose meaning is more specific than "Darbepoetin alfa".
This graph shows the total number of publications written about "Darbepoetin alfa" by people in this website by year, and whether "Darbepoetin alfa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 1 | 2 |
| 2018 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Darbepoetin alfa" by people in Profiles.
-
Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study. ESC Heart Fail. 2018 12; 5(6):1052-1059.
-
T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF. Clin Res Cardiol. 2019 Feb; 108(2):133-141.
-
Optimizing the use of darbepoetin-a with a split strategy: A concept change?. Clin Nephrol. 2018 Feb; 89(2):113-119.
-
Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic Associations. Circ Heart Fail. 2018 02; 11(2):e004431.
-
Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. Eur J Heart Fail. 2018 02; 20(2):268-277.
-
Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis. J Nephrol. 2018 06; 31(3):321-332.